Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Insmed Inc. (INSM) -- Ignore unavailable to you. Want to Upgrade?

To: mopgcw who wrote (110)	12/9/2005 12:50:47 PM
From: tom r. phillips	Read Replies (1) \| Respond to of 136

FDA decision due very soon on approval of Iplex (formerly "Somatokine"); possibility of orphan drug status is clouded by existence of approved competitor (Tercica's product, Increlex), which may or may not be considered different in safety and substance. Tercica's product has been approved, has orphan status, and is nearing commercial launch. Tercica has taken legal action against Insmed, and on and on.... quite a mess, but INSM has run up 30% over last couple weeks on speculation of approval and, perhaps, orphan status based on better safety. Tom